Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer

被引：2

作者：

El Melegy, N. T. ^{[1
]}

Aboulella, H. A. ^{[2
]}

Abul-Fadl, A. M. ^{[1
]}

Mohamed, N. A. ^{[1
]}

机构：

[1] Assiut Univ, Fac Med, Dept Biochem, Assiut, Egypt

[2] Assiut Univ, Fac Med, Dept Urol, Assiut, Egypt

来源：

BRITISH JOURNAL OF BIOMEDICAL SCIENCE | 2010年 / 67卷 / 03期

关键词：

N-Acetylneuraminic acid; Prostate-specific antigen; Prostatic hyperplasia; Prostatic neoplasms; SERUM SIALIC-ACID; CATHEPSIN-D; ANTIGEN RATIO; MEN; DIAGNOSIS; MARKER; LEVEL; AGE;

D O I：

暂无

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

This study aims to evaluate the role of free/total prostate-specific antigen (PSA) ratio, serum total sialic acid level and cathepsin D activity in the differentiation of prostate cancer and benign prostatic hyperplasia (BPH). The study looked at 100 patients with BPH, 75 patients with organ-confined or locally advanced prostate cancer, and a control group of 50 healthy volunteers. Prostate cancer patients showed significantly higher total sialic acid level and cathepsin D activity and lower free/total PSA ratio than those in the BPH group. The results suggest that combined measurement of serum total sialic acid and/or cathepsin D activity with free/total PSA ratio could serve as a useful adjunct to conventional diagnostics for the differentiation of prostate cancer and BPH.

引用

下载

页码：109 / 112

页数：4

共 50 条

[21] Prostate inflammation Association with benign prostatic hyperplasia and prostate cancer
Abdel-Meguid, Taha A.
Mosli, Hisham A.
Al-Maghrabi, Jaudah A.
SAUDI MEDICAL JOURNAL, 2009, 30 (12) : 1563 - 1567
[22] DIFFERENTIATION OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE-CANCER EMPLOYING PROSTATIC-SPECIFIC ANTIGEN DENSITY
WOLFF, JM
SCHOLZ, A
BOECKMANN, W
JAKSE, G
EUROPEAN UROLOGY, 1994, 25 (04) : 295 - 298
[23] Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer
He, Jinhua
Han, Zeping
Luo, Wenfeng
Shen, Jian
Xie, Fangmei
Liao, Liyin
Zou, Ge
Luo, Xin
Guo, Zhonghui
Li, Yuguang
Li, Jianhao
Chen, Hanwei
FRONTIERS IN IMMUNOLOGY, 2023, 13
[24] Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia
Kucur, Mine
Isman, Ferruh K.
Balci, Can
Onal, BuIent
Hacibekiroglu, Munire
Ozkan, Ferda
Ozkan, Alper
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2008, 26 (01) : 47 - 52
[25] Prediction of Prostate Cancer in Patients with Benign Prostatic Hyperplasia
Kogan, M.
Iliyash, A.
Chibichyan, M.
Shiranov, K.
UROLOGY, 2012, 80 (03) : S283 - S283
[26] Decision Aids for Benign Prostatic Hyperplasia and Prostate Cancer
Arterburn, David
Wellman, Robert
Westbrook, Emily O.
Ross, Tyler R.
McCulloch, David
Handley, Matt
Lowe, Marc
Cable, Chris
Zeliadt, Steven B.
Hoffman, Richard M.
AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 (02): : E130 - +
[27] Osteopontin expression in prostate cancer and benign prostatic hyperplasia
Tozawa, K
Yamada, Y
Kawai, N
Okamura, T
Ueda, K
Kohri, K
UROLOGIA INTERNATIONALIS, 1999, 62 (03) : 155 - 158
[28] Alcohol and the risk of prostate cancer and benign prostatic hyperplasia
Crispo, A
Talamini, R
Gallus, S
Negri, E
Gallo, A
Bosetti, C
La Vecchia, C
Dal Maso, L
Montella, M
UROLOGY, 2004, 64 (04) : 717 - 722
[29] Leptin in relation to prostate cancer and benign prostatic hyperplasia
Lagiou, P
Signorello, LB
Trichopoulos, D
Tzonou, A
Trichopoulou, A
Mantzoros, CS
INTERNATIONAL JOURNAL OF CANCER, 1998, 76 (01) : 25 - 28
[30] Oxidative Stress in Benign Prostatic Hyperplasia and Prostate Cancer
Pace, Gianna
Di Massimo, Caterina
De Amicis, Daniela
Corbacelli, Carlo
Di Renzo, Laura
Vicentini, Carlo
Miano, Lucio
Ciancarelli, Maria Giuliana Tozzi
UROLOGIA INTERNATIONALIS, 2010, 85 (03) : 328 - 333

← 1 2 3 4 5 →